EUVIMEDEUVIMED entdecken
Crossref

Brain imaging screening (BIS) in metastatic breast cancer (MBC): patients’ and physicians’ perspectives

E. Laakmann, M. van Ramshorst, V. Müller, E. Agostinetto, S. Linn, M. Lambertini, V. Dieras, F. le Du, S. Braga, C. Criscitiello, K. Jerzak, G. Morgan und 7 weitere

Geburtshilfe und Frauenheilkunde · 01.10.2024 · 84 (10) · e168-e169

DOI: 10.1055/s-0044-1790830 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Geburtshilfe und Frauenheilkunde, erschienen am 01.10.2024. Verfasst von E. Laakmann und 18 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Routinely BIS in patients with MBC without neurological symptoms is not currently recommended, as no survival/quality-of-life improvements have been demonstrated. We investigated physicians and patients’ perspectives.

Methods

Anonymous questionnaires for BC patients and BC-treating physicians were distributed online between 05/2023-02/2024. Data on demographics, treatments and physicians’/patients’ preferences were collected.

Results

545 patients from 14 European countries completed the questionnaire. Median age was 50 years and most had high education levels (73%). 86% had MBC, 51% hormone receptor-positive (HR+)/HER2-negative, 31% HER2-positive and 18% triple negative (TN) BC. 86% of patients, especially younger ones (p=0.02) and with HR- disease (p=0.03), were willing to undergo BIS for asymptomatic brain metastases (BM), despite the uncertain clinical benefit. 529 physicians from 50 countries (80% Europe) completed the questionnaire. Most were medical oncologists (71%) working in academic hospitals (53%). 52% of physicians sometimes/rarely request BIS, mainly when extracranial progression occurs and especially for HER2+ and TN MBC. Among physicians never recommending BIS (35%), 59% would do it if recommended by guidelines, 93% in case of clinical benefit and 32% if ≥ 30% likelihood of BM detection. Notably, 86% of patients would like to receive information on BM development while only 13% of physicians always address the issue.

Conclusions

Our results highlight the need of dedicated clinical trials investigating the clinical value of BIS for asymptomatic MBC. They also underline the willingness of BC patients to know more about the possibility and implications of BM development. Publication History Article published online: 01 October 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Laakmann, E., Ramshorst, M. V., Müller, V., Agostinetto, E., Linn, S., Lambertini, M., Dieras, V., Du, F. L., Braga, S., Criscitiello, C., Jerzak, K., Morgan, G., Brucker, S., Kroge, P. V., Haidinger, R., Schumacher-Wulf, E., Sousa, M. F., Schettini, F., & Matos, L. (2024). Brain imaging screening (BIS) in metastatic breast cancer (MBC): patients’ and physicians’ perspectives. Geburtshilfe und Frauenheilkunde, 84(10), e168-e169. https://doi.org/10.1055/s-0044-1790830

Vancouver

Laakmann E, Ramshorst MV, Müller V, Agostinetto E, Linn S, Lambertini M, et al. Brain imaging screening (BIS) in metastatic breast cancer (MBC): patients’ and physicians’ perspectives. Geburtshilfe und Frauenheilkunde. 2024;84(10):e168-e169. doi:10.1055/s-0044-1790830

BibTeX
@article{Laakmann2024,
  author = {Laakmann, E. and Ramshorst, M. van and Müller, V. and Agostinetto, E. and Linn, S. and Lambertini, M. and Dieras, V. and Du, F. le and Braga, S. and Criscitiello, C. and Jerzak, K. and Morgan, G. and Brucker, S. and Kroge, P. von and Haidinger, R. and Schumacher-Wulf, E. and Sousa, M. Fontes and Schettini, F. and Matos, L.},
  title = {Brain imaging screening (BIS) in metastatic breast cancer (MBC): patients’ and physicians’ perspectives},
  journal = {Geburtshilfe und Frauenheilkunde},
  year = {2024},
  volume = {84},
  number = {10},
  pages = {e168--e169},
  doi = {10.1055/s-0044-1790830}
}
Kostenlos starten →